TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06326138
Drug: Edoxaban Pharmacokinetics and Pharmacodynamics
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be received single oral doses of edoxaban 60 mg.
Study: NCT06444399
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg administered orally twice daily for 24 weeks.
Study: NCT05718011
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
Study: NCT05718011
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
Study: NCT04838678
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-arterial infusion of neuropeptide Y
Study: NCT05679401
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Study: NCT06025773
Drug: Lansoprazole 15 mg
Normalized name: lansoprazole 15 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD-2121 (Lansoprazole 15 mg), Oral, Capsule
Study: NCT04544592
Drug: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
Normalized name: Lapine T-lymphocyte immune globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
Study: NCT04830813
Drug: Chiauranib
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
Study: NCT04639245
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04639245
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05439603
Drug: ANC-501
Normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five 10 mg capsules per day
Study: NCT05852574
Drug: CP-101
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid.
Study: NCT05939882
Drug: low concentration atropine (0.01%)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low concentration atropine (0.01%)
Study: NCT05939882
Drug: low concentration atropine (0.02%)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low concentration atropine (0.02%)
Study: NCT05939882
Drug: low concentration atropine (0.04%)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low concentration atropine (0.04%)
Study: NCT06088017
Drug: CKD-391(2)
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06292286
Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
Study: NCT06292286
Drug: Bevacizumab or biosimilar
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Optional
Study: NCT00000982
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000982
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05189717
Drug: HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
Study: NCT04879589
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ATRS-2002
Study: NCT05714176
Drug: Ferric Pyrophosphate Liposomal
Normalized name: ferric pyrophosphate liposomal
DrugBank: Ferric pyrophosphate (DB09147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
Study: NCT05714176
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
Study: NCT05714176
Drug: Iron Dextran Injection
Normalized name: Iron Dextran Injection
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
Study: NCT05930223
Drug: VAL-1221
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VAL-1221 20mg/kg intravenous (IV) infusion every other week
Study: NCT04992312
Drug: Glucagon Nasal Powder [Baqsimi]
Normalized name: glucagon Nasal Powder [Baqsimi]
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intranasally
Study: NCT04370301
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04370301
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04370301
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04370301
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and PO
Study: NCT04945733
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered intravenously.
Study: NCT05479877
Drug: Biodentine (Septodont, Saint-Maur-des-Fossés, France)
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
Study: NCT01529892
Drug: A single oral 5 mg of duterium labeled methamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04234477
Drug: Beta-blocker strategy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
Study: NCT05478473
Drug: Chidamide combined with Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
Study: NCT06238544
Drug: HRS-5965 tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5965 tablets until the end of study treatment
Study: NCT06489951
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally
Study: NCT05578820
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiviral drug, Intravenous administration
Study: NCT04149145
Drug: M4344+Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
Study: NCT04149145
Drug: M4344+Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
Study: NCT06450899
Drug: Prochlorperazine Maleate
Normalized name: Prochlorperazine Maleate
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Currently, prochlorperazine maleate is approved by the FDA for the treatment of nausea and vomiting, and additionally used off-label as an acute migraine treatment. The FDA has approved the dose of 5-10 mg to be taken orally 3-4 times a day. The study intervention will be obtained from Belmar Pharma solutions. Individuals randomized into the study arm will receive generic prochlorperazine maleate 10 mg orally taken three times daily for one day. Participants will convene in the morning of the trial date at low altitude, where they will receive their first dose. They will then be driven to Summit Lake and break for lunch, where they will receive their second dose approximately 6 hours later. They will then hike to the summit and receive their final dose in the evening, approximately another 6 hours later.
Study: NCT04981886
Drug: Netarsudil Ophthalmic
Normalized name: netarsudil ophthalmic
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be randomly assigned to this group
Study: NCT04981886
Drug: Bimatoprost Ophthalmic
Normalized name: bimatoprost ophthalmic
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be randomly assigned to this group
Study: NCT04922944
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose COVID-19 vaccine
Study: NCT05604859
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
Study: NCT05604859
Drug: intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
Study: NCT05604859
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab:4mg/kg, once
Study: NCT06177496
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of HCC
Study: NCT01538680
Drug: Regorafenib (BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol
Study: NCT05276726
Drug: JAB 21822
Normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05017116
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take orally.
Study: NCT06566989
Drug: [¹⁴C]Opevesostat
DrugBank: Opevesostat (DB18818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT06566989
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT06566989
Drug: Fludrocortisone
Normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03708926
Drug: Abaloparatide
Normalized name: Abaloparatide
DrugBank: Abaloparatide (DB05084)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: abaloparatide injection pen
Study: NCT04251715
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intraarterially via HAI pump
Study: NCT04251715
Drug: Floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intraarterially via HAI pump
Study: NCT04251715
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04251715
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05002127
Drug: Evorpacept (ALX148)
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Q2W
Study: NCT05002127
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Q2W
Study: NCT05002127
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Q2W
Study: NCT05002127
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Days 1, 8, and 15 of a 28-day cycle
Study: NCT04984616
Drug: 40 mg Atorvastatin/day for 120 days P.O.
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Atorvastatin 40 mg/daily for 120 days
Study: NCT04984616
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Atorvastatin 80 mg/daily for 120 days
Study: NCT04986072
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
Study: NCT04986072
Drug: 5% Dextrose solution
Normalized name: Plasma-Lyte M in 5% Dextrose Solution for Injection
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
Study: NCT06065371
Drug: Sacituzumab govetican
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5.
Study: NCT06547502
Drug: GZR4
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT06144749
Drug: HBI-002
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid carbon monoxide drug product.
Study: NCT04645355
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
Study: NCT05274997
Drug: YY-20394
Normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
Study: NCT06087653
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
Study: NCT04939441
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
Study: NCT05221658
Drug: HLX07+HLX10+ Cisplatin+5-FU
Normalized name: 5-FU
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
Study: NCT05221658
Drug: HLX07
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 1000mg iv Q2w
Study: NCT05228873
Drug: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
Study: NCT06242132
Drug: Clopidogrel tablet
Normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT06242132
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT03770546
Drug: Betamethasone injection
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
Study: NCT06413992
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.
Study: NCT06413992
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
Study: NCT06413992
Drug: paclitaxel (albumin bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
Study: NCT06413992
Drug: Carboplatin injection
Normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
Study: NCT06413992
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
Study: NCT04730258
Drug: CFI-400945
Normalized name: Cfi-400945 free base
DrugBank: Ocifisertib (DB18746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
Study: NCT04730258
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine will be given at its labeled dose and schedule
Study: NCT05465317
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin
Study: NCT05465317
Drug: Dipeptidyl Peptidate-4 inhibitors
Normalized name: PEPTIDE-T
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl Peptidate-4 inhibitors